Navigation Links
Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
Date:1/31/2008

Company to Conduct Conference Call and Webcast

LEXINGTON, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) will announce its first quarter fiscal 2008 financial results in a press release to be issued before market open on Thursday, February 7, 2008. The Company will host a conference call and webcast to discuss these results at 9:00 AM eastern time on Thursday, February 7, 2008.

The live call may be accessed by dialing 888-680-0893 from the U.S. and Canada, and 617-213-4859 from international locations. The participant passcode is 93441269. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PWJFVJ69C. Pre- registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection. A replay of the call will be available beginning at 11:00 AM on February 7, 2008 and lasting until 12:00 AM on March 7, 2008. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801- 6888 from international locations, using the passcode 15551448.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, http://www.indevus.com. An archived version of the call will be accessible at the same web address for 30 days following the live call.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharm
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
2. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
3. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
4. Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study
5. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
6. Skinvisible Announces Licensing Agreement for Adapalene
7. Aflac Incorporated Announces Fourth Quarter Results
8. Hologic Announces Two-For-One Stock Split
9. Hutchinson Center Announces First Unclimbed Mountain to be Tackled by Big Expedition for Cancer Research
10. Healthcare Businesswomens Association Announces 2008 Board of Directors
11. Perdue AgriBusiness Announces Low Linolenic Soybean Contracting Opportunities with DuPont Business Pioneer Hi-Bred

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...swire/ -- The American Association of Homes and Se...or passing Sen. Michael Bennet,s (D-Colo.) amendme...ed benefits, and strengthens Medicare by keeping s...tsunami of retiring baby boomers fast approaching,... currently before Congress to address Medicare,s s...
(Date:12/3/2009)...re,s cult favorite Drying Lotion picked by ELLE Re...LLE Beauty Award , (PRWEB...ying Lotion has long been a cult favorite among ce... divas, but its selection by ELLE readers for a 20...o the mainstream limelight., , , , ,The ELLE Beau...
(Date:12/3/2009)...ent Clinics Also Remain Open , ...ra Health System is continuing to offer H1N1 nasal...Primary Care (CPC) vaccination clinics since ano...are at CPC sites in Huntley, Woodstock, Crystal La...nbsp; From 4:30 to 7:30 p.m. Thursday, Dec. 3 ...
(Date:12/3/2009)...Chiltern International Limited (Chiltern), a globa...linical development and staffing services in Europ...intment of Dr. Sharon Moore as Executive Vice Pr... Moore is based at Chiltern,s Bristol, Tennessee, ... years of industry experience. Prior to joining Ch...
(Date:12/3/2009)...s key factors contributing to increases ,, WAS...ctuarial analysis by Oliver Wyman, Inc. finds that...al market will be 54 percent higher than they are ...e reform under the Patient Protection and Affordab...al inflation. This would translate into premiums ...
Breaking Medicine News(10 mins):Health News:Centegra H1N1 Vaccination Clinics Continue 2Health News:Centegra H1N1 Vaccination Clinics Continue 3Health News:Centegra H1N1 Vaccination Clinics Continue 4Health News:Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 2Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 3Health News:New Actuarial Analysis Shows Senate Bill Would Significantly Raise Premiums 4
...up of fertility specialists marks its 25th anniver...challenged by economic downturn , , SAN RAMON, Ca...ration, one of the nation,s first fertility clinic...omic climate nationwide. , , Established just two...
... Feb. 16 AlphaVax announced today that it has h...ory, Quality and Clinical Operations. In this capa...rection in the areas of regulatory and quality aff...y approval for clinical trials will complement our...
...but not replace, standard screening, they say , ...ould supplement and enhance current screening and ...itute for it, according to newly released physicia...t MRI, a relatively new clinical tool. , "Health ...
...vironmental Tectonics Corporation (NYSE ALTERNEXT ...ced that on February 11, 2009, it received a lette... American Stock Exchange, stating that the Company...al basis. , , The non-compliance with Section 704...
...often deserving 2009 SSI Disability cases will not...e of mistakes made on the disability application. ...iates advise disabled consumers to take additional...ll help ensure your 2009 SSI Disability applicatio...
...09)P&G Beauty & Grooming scientists are presenting.... 12-16) that offers evidence of science,s role in...his year,s meeting theme observes the 200th annive... feel and look their best. Five studies--with subj...
Other Medicine News:Health News:Bay Area Fertility Clinic to Offer Special Help During Recession 2Health News:AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations 2Health News:Experts Release Guidelines on Use of Breast MRI 2Health News:Environmental Tectonics Corporation Reports Receipt of Non-Compliance Notice from NYSE Alternext US LLC 2Health News:Environmental Tectonics Corporation Reports Receipt of Non-Compliance Notice from NYSE Alternext US LLC 3Health News:SSI Disability Application Tips for 2009 2Health News:SSI Disability Application Tips for 2009 3Health News:SSI Disability Application Tips for 2009 4Health News:SSI Disability Application Tips for 2009 5Health News:Beauty and grooming science evolves 2Health News:Beauty and grooming science evolves 3
(Date:12/3/2009)....C., Dec. 3 In response...nformation technologies in the evolving healthcare...ke Center for Health Informatics (DCHI) to provide...oversee an innovative interdisciplinary approach t...physicians, nurses and healthcare administrators w...
(Date:12/3/2009)...O, Dec. 3 Cardium Therap... wholly-owned subsidiary, Tissue Repair Company, s...th the U.S. Food and Drug Administration (FDA) see...roduct candidate based on positive data from the C...al study. Today,s submission with the FDA covers ...
(Date:12/3/2009)...inn., Dec. 3 Apnex Medical, Inc., ...t has completed a second round of private equity f...sed to complete a clinical study and develop a sec...nology designed to treat obstructive sleep apnea (...Domain Associates, New Enterprise Associates (NEA)...
Breaking Medicine Technology:Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 2Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 3Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 4Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds 5Apnex Medical, Inc. Raises Additional $14 Million 2Apnex Medical, Inc. Raises Additional $14 Million 3This Fathers Day Give Dad a Gift Straight for the Heart 49181 1This Fathers Day Give Dad a Gift Straight for the Heart 49181 2This Fathers Day Give Dad a Gift Straight for the Heart 49181 3URAC Stresses Importance of Standards for Wellness Programs and Health Plan at AHIP Institute 2009 49179 1URAC Stresses Importance of Standards for Wellness Programs and Health Plan at AHIP Institute 2009 49179 2URAC Stresses Importance of Standards for Wellness Programs and Health Plan at AHIP Institute 2009 49179 3China Biotics Inc to Join Russell 3000 Index 12669 1China Biotics Inc to Join Russell 3000 Index 12669 2China Biotics Inc to Join Russell 3000 Index 12669 3
... Volunteers to be Presented at ...harmaceuticals,Inc. (Nasdaq: ANDS ) announced tod... of ANA598 in healthy volunteers and finalization ...patients chronically infected,with hepatitis C vir...as,well tolerated at all doses analyzed to date an...
...ASE: BIOV) from Rehovot, Israel, reported today re...vasive diagnostic test under development for,early...of 76 sputum samples were collected from four,grou...er smoked 2. Heavy smokers with no signs of lung ... 1) 4. Advanced stage lung cancer patients, The ...
Other Medicine Technology:Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 2Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 3Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 4Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 5Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients 6BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test 2
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
...P Laboratories is a national reference laboratory ...search and development. ARUP offers an extensive t...s in clinical and anatomic pathology. Owned by the...clude more than half of the nation's university te...
Medicine Products: